Navigation Links
Innocoll Receives 'Intends to Grant' Notices from the European Patent Office for Two European Patent Applications Related to Novel Wound Healing, Biosurgery and Drug Delivery Applications of its CollaRx(R) Technology
Date:11/28/2007

cers and pressure sores.

The '648 patent describes a novel, fully biodegradable and resorbable collagen-based material with improved mechanical, physical and functional properties that has application as a wound covering or surgical implant for the purpose of tissue augmentation and repair where mechanical strength is especially desirable. The material may optionally contain drugs and other bioactive substances for local delivery to the site of implantation or tissue defect.

Commenting on receipt of the notices, Dr. Michael Myers, President and CEO said, "The grant of these two patents will both broaden and strengthen the intellectual property covering our core CollaRx platform technology and particularly its applications in wound healing, biosurgery and local drug delivery. Having now secured both European and US patent rights for our advanced wound care product, DermaSIL, we are intent on scaling-up the proprietary manufacturing process and commercializing this product in 2008 through our CollMED Laboratories joint venture in the US and in collaboration with distribution partners in Europe."

About CollaRx(R)

CollaRx is Innocoll's lead technology platform for the site specific, local delivery of a wide variety of drugs with particular emphasis on antibiotics, anesthetics, anti-cancer agents and tissue regeneration proteins and peptides. The CollaRx technology forms the basis of Innocoll's lead product, Gentamicin Surgical Implant, a biodegradable leave-behind implant indicated for the treatment and prevention of surgical site infection in both hard and soft tissue. This product is already approved in 49 countries and is in phase 3 development in the US. Other CollaRx sponge products under clinical development by Innocoll include a CollaRx Bupivacaine Implant for the management of post-operative pain and a topically-applied CollaRx Gentamicin Sponge for the treatment and prevention of diabetic foot infections. Innocoll's CollaRx membrane
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
2. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
3. DaVita Receives Civil Complaint
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
5. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
6. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
7. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
8. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
9. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
10. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
11. Prime Therapeutics Receives TIPPS Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...t therapy given during surgery extends survival ti...fe expectancy in non-small cell lung cancer (NSCLC...e is very hard to treat, especially when it has sp...ors at Thomas Jefferson University Hospital, Phila...
...rson aged 40 or over has a lifetime risk of heart ...ave high blood pressure. Heart failure is an incre...ed by increasing pressure within the heart which m...body. Typical symptoms are breathlessness and fati...
...prescribed medicines by the doctor are to be verif...ay an important role in helping you. Experts at th...t of your health care team, alongside your physici... your medications dispensed at the once pharmacy. ...
... coughs are harmless, while others merit medical a..., symptom. Most often it's part and parcel of a co...o spread the infection, there's little you can do....a more serious underlying medical condition. Doct...
Other Medicine News:
(Date:8/14/2008)...Newswire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq: ...mmitted to,discovering, developing and commerciali...ed unaudited financial results for the third fisca... a net loss attributable to,common stockholders of...he,quarter ended June 30, 2008, as compared to a n...
(Date:8/14/2008)...14 /- The Clinical Trials,Bootcamp an...hysicians,clinical coordinators, clinical researc...It will be held in Boca Raton at the Boca Resort f...inical coordinators, monitors and,other industry p...orporate,clinical trials into a practice, as well ...
(Date:8/14/2008)...begin in late 2008 or in early 2009 -, SAN CARLOS..., Inc.,(Nasdaq: NUVO ) today announced positive r... NU172, demonstrating that the direct thrombin,inh...tion with a rapid,return toward baseline after the... "NU172 has the potential to address many of the l...
(Date:8/13/2008)...-FirstCall/ -- As biotechnology,pharmaceutical an...cal,trials beyond their own borders to other parts...uth America, complicated regulatory environments,c...rding to an analysis by,Aon Corporation (NYSE: AO...those companies a visual representation of the com...
Breaking Medicine Technology:Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 2Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 3Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 4Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 5Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 6Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 7Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 8Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 9Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 2Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 3Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 4Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 4Consumers Health Care Purchasers Applaud Agreement On Physician Performance Reporting 4851 1Consumers Health Care Purchasers Applaud Agreement On Physician Performance Reporting 4851 2Consumers Health Care Purchasers Applaud Agreement On Physician Performance Reporting 4851 3Consumers Health Care Purchasers Applaud Agreement On Physician Performance Reporting 4851 4Dead clams tell many tales 1007 1Dead clams tell many tales 1007 2Dead clams tell many tales 1007 3Dead clams tell many tales 1007 4Tiny radioactive spheres effectively treat cancer that has spread to the liver 4844 1Tiny radioactive spheres effectively treat cancer that has spread to the liver 4844 2New treatment option studied for bladder cancer 4839 1New treatment option studied for bladder cancer 4839 2New treatment option studied for bladder cancer 4839 3
...curs at the 55th Annual,Clinical Meeting of the Am... COLLEGEVILLE, Pa., May 09, 2007 /PRNewswire-First...h , presented results from the,first Phase 3 studi... treatment of moderate-to-severe vasomotor symptom...enopause. These studies showed,that women who took...
...- Results of a Phase 2a,clinical trial evaluating ...eat hospital acquired gram-negative bacterial,pneu...ociety (ATS),International Conference, May 18 - 23...S. Niederman, MD, Chairman, Department of, ...or of, Medicine; Vice Chairman, Departme...
Other Medicine Technology:Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 2Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 3Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 4Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 5Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 6Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 2Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 3
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
Medicine Products: